TROPION-Lung01 Study Design and Baseline demographics
BEGONIA Arm 7: Dato-DXd + Durvalumab
Conclusions
Dato-DXd + durvalumab continues to demonstrate robust, durable responses in first-line
a/mTNBC in a biomarker-unselected population with median 11.7 months of follow-up
Confirmed ORR was 79% (95% CI, 66.8–88.3), responses observed regardless of PD-L1 expression
Median DoR was 15.5 months (95% CI, 9.92-NC)
Median PFS was 13.8 months (95% CI, 11.0-NC)
The combination of Dato-DXd + durvalumab had a tolerable and manageable safety profile,
with no new safety signals
Comprehensive toxicity management guidelines were implemented during the course of the study
BEGONIA is currently enrolling for Arm 8, Dato-DXd + durvalumab in a PD-L1-high population
a/mTNBC, advanced/metastatic triple-negative breast cancer; CI, confidence interval; Dato-DXd, datopotamab deruxtecan; DoR, duration of response; NC, not calculable; ORR, objective response rate; PD-L1, programmed death ligand-1; PFS, progression-free survival.
43
33
Daiichi-SankyoView entire presentation